Carmell Therapeutics closed a US $4MM Series B financing. Funds will support Phase III clinical development of Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product designed to treat bone fractures while reducing complications, infections and duration of care.
PBM technology allows for controlled release of growth and healing factors to bone and soft tissues at an injured site. PBMs can be manufactured to fit forms such as putties, pastes, scaffolds, plugs, screws and sheets.
Financing participants included current investors Pittsburgh Life Sciences Greenhouse, Harbor Light Capital, Newlin Investments and BlueTree Capital, with new investor Keiretsu Forum Capital.
Carmell Therapeutics closed a US $4MM Series B financing. Funds will support Phase III clinical development of Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product designed to treat bone fractures while reducing complications, infections and duration of care.
PBM technology allows for controlled release of growth...
Carmell Therapeutics closed a US $4MM Series B financing. Funds will support Phase III clinical development of Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product designed to treat bone fractures while reducing complications, infections and duration of care.
PBM technology allows for controlled release of growth and healing factors to bone and soft tissues at an injured site. PBMs can be manufactured to fit forms such as putties, pastes, scaffolds, plugs, screws and sheets.
Financing participants included current investors Pittsburgh Life Sciences Greenhouse, Harbor Light Capital, Newlin Investments and BlueTree Capital, with new investor Keiretsu Forum Capital.
Copy to clipboard 
